Johnson & Johnson’s TREMFYA® Shows Sustained One-Year Efficacy in Ulcerative Colitis
SPRING HOUSE, PA — Johnson & Johnson (NYSE: JNJ) released new 48-week results from its Phase 3 ASTRO study evaluating TREMFYA® (guselkumab) as a subcutaneous induction and maintenance therapy for …
Johnson & Johnson’s TREMFYA® Shows Sustained One-Year Efficacy in Ulcerative Colitis Read More